Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
BIIB · against 1,336 other Healthcare companies
Ranked #516 of 1,337 · scores higher than 61% of peers
Bars: peers in each 10-point band of the valuation score134 peers with a valuation score of 60–69, including BIIB · Click a bar to see the companies
Mainly thanks to its free cash flow yield and EBITDA yield, which are stronger than most Healthcare peers.
| Metric | BIIB | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | 2.3% | 1.5% | 56% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | 7.7% | 4.2% | 71% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | 6.8% | -1.0% | 87% | 20% | |
| Book yieldHigher is better · 1,306 reported | 51.3% | 37.9% | 63% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 516 | 406.2B KRW (≈$292M) | 61 | 51 | |
| 516 | 231.7B JPY (≈$1.6B) | 61 | 61 | |
| 516 | 16.3B CNY (≈$2.3B) | 61 | 49 | |
| 516 | 626.0B INR (≈$7.5B) | 61 | 68 | |
| 516 | 36.8B USD | 61 | 46 | |
| 516 | 1.2B USD | 61 | 67 | |
| 516 | 10.6B USD | 61 | 64 | |
| 516 | 4.4B CHF (≈$5.1B) | 61 | 47 | |
| 516 | 1.1B CAD (≈$807M) | 61 | 60 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score